General Information

Zoom LINKS

Main Room/Workshop A - https://uky.zoom.us/j/81364495733

Workshop B - https://uky.zoom.us/j/87040319611

Workshop C - https://uky.zoom.us/j/82743429578

Presentations can be found https://www.cecentral.com/live/20814/files

EVALUATION LINK - https://uky.az1.gualtrics.com/jfe/form/SV 9tLbGCGVwaFn1wW



GET CREDIT INSTRUCTIONS will be emailed to everyone in attendance at the conclusion of the activity.

ACCREDITATION



In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME

This live activity is designated for a maximum of 12.50 *AMA PRA Category 1 Credit*(s)TM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

IPE Competencies

- Values/Ethics for Interprofessional Practice
- Roles/ Responsibilities

- Interprofessional Communication
- Teams and Teamwork

CNE

The maximum number of hours awarded for this Continuing Nursing Education activity is 12.50 nursing contact hours.

ASWB ACE

As a Jointly Accredited Organization, UK HealthCare CECentral is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. UK HealthCare CECentral maintains responsibility for this course. Social workers completing this course receive 4.5 continuing education credits

OBJECTIVES

Upon competition of this activity, participants will be able to:

- 1. Discuss the importance of participating in the Alliance for Innovation on Maternal Health's patient safety bundles.
- 2. Discuss the safety and efficacy of MAT and how to access the resources to connect with other providers who manage MAT in different care settings.
- 3. Describe the importance about eliminating stigma towards pregnant and parenting women with substance use disorder.
- 4. Review the importance of using a validated screening tool and universal screening for substance use disorder in pregnancy.
- 5. Define the importance of breastfeeding and it's nutritional bene tf for infants born with NAS.
- 6. Discuss successful quality improvement initiatives from other states
- 7. Identify successful quality improvement initiatives and strategies that could be applied in Kentucky.

FINANCIAL DISCLOSURE SUMMARY

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

Haywood Brown, MD faculty for this educational event, is on the Advisory Board for Merck Global Health; medical advisor for Carrier Screening Coalition; consultant for Myriad; & consultant medical for Hologic.

Dena Goffman, MD, faculty for this educational event, is on the advisory board of Roche Preeclampsia and on the safety Council for Cooper Surgical Obstetrical.

Audra Meadows, MD, faculty for this educational event, is a consultant for the Institute for Perinatal Quality Improvement.

Paula Schreck, MD, faculty for this educational event, is a consultant for KY Department of Public Health and the Louisiana Bureau of Family Health; WK Kellogg Foundation grantee and Employee for Coffective LLC.

All of the relevant financial relationships listed for these individuals have been mitigated.

None of the other planners, faculty, and others in control of educational content for this educational activity have relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.